COPD management. Part II. Relevance for resource-poor settings

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 6, 2008, Pages 595-600

  Ait Khaled N ^a,b   Enarson, D A ^a   Chiang, C Y ^a  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b International Union Against Tuberculosis and Lung Disease   (France)

Author keywords

COPD; Low income countries; Management; Resources

Indexed keywords

BECLOMETASONE; IPRATROPIUM BROMIDE; SALBUTAMOL; THEOPHYLLINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; GOVERNMENT; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; INFECTION; ORGANIZATION; OXYGEN THERAPY; PATIENT CARE; POLITICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; RESPIRATORY TRACT DISEASE; REVIEW; SPIROMETRY; WORLD HEALTH ORGANIZATION;

DEVELOPING COUNTRIES; HEALTH EXPENDITURES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SPIROMETRY; WORLD HEALTH;

EID: 45349099348     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Ciba Guest Symposium. Terminology, definitions, and classification of chronic pulmonary emphysema and related conditions: a report of the conclusions of a Ciba Guest Symposium. Thorax 1959; 14: 286-299.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Based on 1998 National Heart, Lung, and Blood Institute/WHO report. NIH, NHLBI Publication No. 2701. Bethesda, MD, USA: NHBLI, 2005. http://www.goldcopd.org
3. World Health Organization. Preventing chronic diseases: a vital investment. Geneva, Switzerland: WHO, 2005. http://www.who.int//chp// chronic_disease_report/contents/en/index.html Accessed 5 Dec 2007.
4. World Health Organization. World health report 2004: changing history. Statistical Annex 127-131. Geneva, Switzerland: WHO, 2004.
5. Menezes A M, Perez-Padilla R, Jardim J B, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875-1881.
6. Buist A S, McBurnie M A, Vollmer W M, et al. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
7. Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med 2007; 176: 753-760.
8. Aït-Khaled N, Enarson D A, Ottmani S, El Sony A, Eltigani M, Sepulveda R. Chronic airway limitation in developing countries: burden and priorities. Int J Chron Obstruct Pulmon Dis 2007; 2: 141-150.
9. Aïr-Khaled N, Auregan G, Bencharif N, et al. Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. Int J Tuberc Lung Dis 2000; 3: 268-271.
10. World Health Organization. National health accounts: country information. Geneva, Switzerland: WHO, 2007. http://www.who.int/nha/country Accessed March 2008.
11. Aït-Khaled N, Enarson D A, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ 2001; 79: 971-979.
12. World Health Organization. A global atlas on the health workforce [online database]. Geneva, Switzerland: WHO, 2006. http://who.int/globalatlas/ autologin/hrh_login.asp Accessed March 2008.
13. World Health Organization. Resolution WHA53.17. Prevention and control of noncommunicable diseases. In: 53rd World Health Assembly, Geneva, 15-20 May 2000. Volume I. Resolutions and decisions, annex. WHA53/2000/REC/1. Geneva, Switzerland: WHO, 2000: pp 22-24.
14. World Health Organization. Framework convention on tobacco control. Technical briefing series. WHO/NCD/TF1/99. Geneva, Switzerland: WHO, 1999.
15. World Health Organization. WHO report 2007. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2007.376. Geneva, Switzerland: WHO, 2006.
16. Rabe K F, Hurd S, Anzueto A, Barnes P J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
17. Aït-Khaled N, Chaulet P, Enarson D A, Slama K. Epidemiology and management of stable chronic obstructive pulmonary disease in Africa. In: Similowski T, Derenne P. Clinical management of clinical obstructive pulmonary disease. New York, NY, USA: Marcel Dekker, 2002.
18. Chan-Yeung M, Aït-Khaled N, White N, Tsang K W, Tan W C. Management of chronic obstructive pulmonary disease in Asia and Africa. Int J Tuberc Lung Dis 2004; 8: 159-170.
19. Price D B, Tinkelman D G, Halbert R J, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration 2006; 73: 285.
20. Tinkelman D G, Price D B, Nordyke R J, et al. Symptom-based questionnaire for differentiating COPD and asthma. Respiration 2006; 73: 296-305.
21. Ottmani S E, Sherpbier R, Pio A, et al. Practical approach to lung health (PAL). A primary health care strategy for the integrated management of respiratory conditions in people five years of age and over. WHO/HTM/TB/2005.351. Geneva, Switzerland: WHO, 2005.
22. Williams M, De Palma L, Cafarella P, Petkov J. Fifteen-count breathlessness score in adults with COPD. Respirology 2006; 11:627-632.
23. Badgett R G, Tanaka D J, Hunt D K, et al. The clinical evaluation for diagnosing obstructive airways disease in high-risk patients. Chest 1994; 106: 1427-1431.
24. Miller M R, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
25. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung tests function. Eur Respir J 2005; 26: 948-968.
26. National Institutes of Health, National Heart, Lung and Blood Institute. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report. NIH publication number 95-3659. Bethesda, MD, USA: NHLBI, 1995. Revision 2006. www.ginasthma.com
27. Aït-Khaled N, Enarson D. Management of asthma in adults. A guide to the essentials of good clinical practice. Paris, France: International Union Against Tuberculosis and Lung Disease, 2005. www.iuatld.org
28. Slama K. Tobacco control and prevention. A guide for low-income countries. Paris, France: International Union Against Tuberculosis and Lung Disease, 1998.
29. Slama K, Chiang C-Y, Enarson D A. Tobacco cessation and brief advice. Int J Tuberc Lung Dis 2007; 11: 612-616.
30. Solberg L I, Maciosek M V, Edwards N M, Khanchandani H S, Goodman M J. Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness. Am J Prev Med 2006; 31: 62-71.
31. Baris E, Ezzati M. Should interventions to reduce respirable pollutants be linked to tuberculosis control programmes? BMJ 2004; 329: 1090-1093.
32. World Health Organization. WHO model list of essential medicines. 15th list. Geneva, Switzerland: WHO, 2007. http://www.who.int/medicines/publications/ EMLl5.pdf Accessed March 2008.
33. Billo N E. Do we need an asthma drug facility? Int J Tuberc Lung Dis 2004; 8: 391.
34. Billo N E. Asthma drug facility: from concept to reality. Int J Tuberc Lung Dis 2006; 10: 709.
35. Aït-Khaled N, Enarson D A, Bissell K, Billo N E. Access to inhaled corticosteroids is key to improving quality of care for asthma in developing countries. Allergy 2007; 62: 230-236.
36. Kolodziej M A, Jensen L, Rowe B, Sin D. Systematic review of noninvasive positive pressure ventilation in severe stable COPD. Eur Respir J 2007; 30: 293-306.